In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 03 2022
02 03 2022
Historique:
received:
17
09
2021
accepted:
14
02
2022
entrez:
3
3
2022
pubmed:
4
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Acute kidney injury (AKI) is associated with increased mortality in most critical settings. However, it is unclear whether its mild form (i.e. AKI stage 1) is associated with increased mortality also in non-critical settings. Here we conducted an international study in patients hospitalized with SARS-CoV-2 infection aiming 1. to estimate the incidence of AKI at each stage and its impact on mortality 2. to identify AKI risk factors at admission (susceptibility) and during hospitalization (exposures) and factors contributing to AKI-associated mortality. We included 939 patients from medical departments in Moscow (Russia) and Padua (Italy). In-hospital AKI onset was identified in 140 (14.9%) patients, mainly with stage 1 (65%). Mortality was remarkably higher in patients with AKI compared to those without AKI (55 [39.3%] vs. 34 [4.3%], respectively). Such association remained significant after adjustment for other clinical conditions at admission (relative risk [RR] 5.6; CI 3.5- 8.8) or restricting to AKI stage 1 (RR 3.2; CI 1.8-5.5) or to subjects with AKI onset preceding deterioration of clinical conditions. After hospital admission, worsening of hypoxic damage, inflammation, hyperglycemia, and coagulopathy were identified as hospital-acquired risk factors predicting AKI onset. Following AKI onset, the AKI-associated worsening of respiratory function was identified as the main contributor to AKI-induced increase in mortality risk. In conclusion, AKI is a common complication of Sars-CoV2 infection in non-intensive care settings where it markedly increases mortality risk also at stage 1. The identification of hospital-acquired risk factors and exposures might help prevention of AKI onset and of its complications.
Identifiants
pubmed: 35236891
doi: 10.1038/s41598-022-07490-z
pii: 10.1038/s41598-022-07490-z
pmc: PMC8891366
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3474Subventions
Organisme : Fondazione Cassa di Risparmio di Padova e Rovigo (Foundation Cariparo)
ID : COOVIDIMED
Informations de copyright
© 2022. The Author(s).
Références
Am J Kidney Dis. 2021 Feb;77(2):204-215.e1
pubmed: 32961245
J Am Soc Nephrol. 2016 Mar;27(3):687-97
pubmed: 26519085
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
PLoS One. 2021 May 3;16(5):e0250602
pubmed: 33939733
Nat Rev Nephrol. 2020 Dec;16(12):747-764
pubmed: 33060844
BMC Pulm Med. 2020 Nov 9;20(1):290
pubmed: 33167955
Mayo Clin Proc Innov Qual Outcomes. 2020 Dec;4(6):687-695
pubmed: 32838205
Radiology. 2020 Aug;296(2):E97-E104
pubmed: 32339082
Kidney Int Suppl (2011). 2012 Mar;2(1):19-36
pubmed: 25018918
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Diabetes Res Clin Pract. 2020 Oct;168:108374
pubmed: 32805345
Crit Care Med. 2006 Jul;34(7):1913-7
pubmed: 16715038
JAMA Netw Open. 2020 Oct 1;3(10):e2019209
pubmed: 33021646
Int J Stat Med Res. 2015;4(3):287-295
pubmed: 27429686
Cureus. 2020 Aug 12;12(8):e9693
pubmed: 32802627
PLoS Med. 2020 Oct 30;17(10):e1003406
pubmed: 33125416
Int J Lab Hematol. 2021 Jul;43 Suppl 1:129-136
pubmed: 33270980
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Am J Nephrol. 2012;35(4):349-55
pubmed: 22473149
Lancet Respir Med. 2020 Jul;8(7):738-742
pubmed: 32416769
J Am Soc Nephrol. 2020 Sep;31(9):2205-2221
pubmed: 32826326
Lung. 2014 Feb;192(1):141-9
pubmed: 24221341
Respir Res. 2005 Jul 21;6:78
pubmed: 16042760
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):14-25
pubmed: 33199414